Development of a Novel Treatment for Cancerous Peritonitis

Development of a Novel Treatment for Cancerous Peritonitis - Development of a Novel Treatment for Cancerous Peritonitis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055308

Enrollment

Registered

2024-08-28

Start date

2022-10-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with cancerous peritonitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with cancerous peritonitis and who require a peritoneal puncture

Exclusion criteria

Exclusion criteria: If the physician determines that the patient is not eligible

Design outcomes

Primary

Measure	Time frame
Confirmation of the efficacy of a novel treatment for patients with refractory cancer ascites by inducing the reactivation of exhausted CD4/CD8 T cells by culturing T cells in ascites fluid with a demethylating agent.	—

Secondary

Measure	Time frame
(1) Confirmation of the efficacy of a novel treatment for patients with refractory cancerous ascites by reactivation of CD4/CD8 T cells using a technology that suppresses PD1 mRNA in T cells using CRISPR/Cas13. (2) Confirmation of the efficacy of T cell staging technology by detection of methylation patterns that can predict the activation state of T cells.	—

Countries

Japan

Contacts

Public ContactTakeshi Nagasaka

Kawasaki Medical School Advanced Oncology

takeshin@med.kawasaki-m.ac.jp0864621111

Outcome results